Conditioning regimens for autologous haematopoietic stem cell transplantation – can natural killer cell therapy help?
Snowden JA et al. Br J Haematol. 2017 Feb 17. doi: 10.1111/bjh.14565. [Epub ahead of print].

Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.
Vogl DT et al. Leuk Lymphoma. 2017 Jan 31:1-11. doi: 10.1080/10428194.2016.1263842. [Epub ahead of print].

Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).
Simões-Pires CA et al. Expert Opin Ther Pat. 2017 Mar;27(3):229-236. doi: 10.1080/13543776.2017.1282945. Epub 2017 Jan 31.

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.
Ludwig H et al. Leukemia. 2017 Feb 3. doi: 10.1038/leu.2017.5. [Epub ahead of print].

CARs in the Lead Against Multiple Myeloma.
Ormhøj M et al. Curr Hematol Malig Rep. 2017 Feb 23. doi: 10.1007/s11899-017-0373-2. [Epub ahead of print].